Log in

NASDAQ:SRRA - Sierra Oncology Stock Price, Forecast & News

$15.48
-0.15 (-0.96 %)
(As of 02/16/2020 04:00 PM ET)
Add
Today's Range
$15.13
Now: $15.48
$16.01
50-Day Range
$0.33
MA: $6.27
$16.70
52-Week Range
$8.62
Now: $15.48
$80.40
Volume35,213 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Sierra Oncology, Inc, a clinical stage drug development company, is advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has been investigated in two completed Phase 3 trials for the treatment of myelofibrosis and has demonstrated a differentiated therapeutic profile encompassing anemia-related benefits, as well as achieving substantive splenic volume reduction and constitutional symptom control. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:SRRA
Previous SymbolNASDAQ:DNAI
CUSIPN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees79
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive SRRA News and Ratings via Email

Sign-up to receive the latest news and ratings for SRRA and its competitors with MarketBeat's FREE daily newsletter.


Sierra Oncology (NASDAQ:SRRA) Frequently Asked Questions

What is Sierra Oncology's stock symbol?

Sierra Oncology trades on the NASDAQ under the ticker symbol "SRRA."

How were Sierra Oncology's earnings last quarter?

Sierra Oncology Inc (NASDAQ:SRRA) posted its quarterly earnings results on Monday, November, 4th. The biotechnology company reported ($0.17) EPS for the quarter, topping the Zacks' consensus estimate of ($0.21) by $0.04. View Sierra Oncology's Earnings History.

When is Sierra Oncology's next earnings date?

Sierra Oncology is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Sierra Oncology.

What price target have analysts set for SRRA?

2 Wall Street analysts have issued 12-month price targets for Sierra Oncology's shares. Their forecasts range from $1.20 to $1.20. On average, they anticipate Sierra Oncology's share price to reach $1.20 in the next twelve months. This suggests that the stock has a possible downside of 92.2%. View Analyst Price Targets for Sierra Oncology.

What is the consensus analysts' recommendation for Sierra Oncology?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sierra Oncology in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sierra Oncology.

Has Sierra Oncology been receiving favorable news coverage?

Press coverage about SRRA stock has trended negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Sierra Oncology earned a news sentiment score of -2.1 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Sierra Oncology.

Are investors shorting Sierra Oncology?

Sierra Oncology saw a decrease in short interest in the month of January. As of January 15th, there was short interest totalling 5,510,000 shares, a decrease of 10.8% from the December 31st total of 6,180,000 shares. Based on an average daily trading volume, of 2,060,000 shares, the short-interest ratio is currently 2.7 days. Approximately 9.5% of the shares of the stock are sold short. View Sierra Oncology's Current Options Chain.

What other stocks do shareholders of Sierra Oncology own?

Who are Sierra Oncology's key executives?

Sierra Oncology's management team includes the folowing people:
  • Dr. Nicholas R. Glover, Pres, CEO & Director (Age 50)
  • Dr. Barbara Klencke, Chief Devel. Officer (Age 62)
  • Dr. Mark M. Kowalski, Chief Medical Officer (Age 64)
  • Mr. Sukhi Jagpal CA, CPA, CBV, MBA, Chief Financial Officer (Age 45)
  • Dr. Keith E. Anderson Ph.D., Sr. VP of Technical Operations (Age 50)

Who are Sierra Oncology's major shareholders?

Sierra Oncology's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (35.74%), Acadian Asset Management LLC (14.18%), Ikarian Capital LLC (4.00%) and Virtu Financial LLC (1.77%). Company insiders that own Sierra Oncology stock include Andrew R Allen and Barbara Klencke. View Institutional Ownership Trends for Sierra Oncology.

Which major investors are buying Sierra Oncology stock?

SRRA stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Acadian Asset Management LLC, Ikarian Capital LLC and Virtu Financial LLC. Company insiders that have bought Sierra Oncology stock in the last two years include Andrew R Allen and Barbara Klencke. View Insider Buying and Selling for Sierra Oncology.

How do I buy shares of Sierra Oncology?

Shares of SRRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Sierra Oncology's stock price today?

One share of SRRA stock can currently be purchased for approximately $15.48.


MarketBeat Community Rating for Sierra Oncology (NASDAQ SRRA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  259 (Vote Outperform)
Underperform Votes:  244 (Vote Underperform)
Total Votes:  503
MarketBeat's community ratings are surveys of what our community members think about Sierra Oncology and other stocks. Vote "Outperform" if you believe SRRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Featured Article: Most Volatile Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel